The QualityStocks Daily Monday, February 11th, 2019

Today's Top 3 StockMarketWatch

MarketBeat (VYST) +127.25%

QualityStocks (RCCMF) +98.90%

Kiplinger Today (SHLDQ) +52.20%

The QualityStocks Daily Stock List

Wize Pharma, Inc. (WIZP)

Dividend Investor, Stockwatch, Capital Cube, Cardinal Weekly, Investors Hangout, Insider Mole, Stockopedia, Penny Stock Hub, Stockhouse, InvestorsHub, Wallmine, OTC Markets, Barchart, MarketWatch, and 4-Traders reported earlier on Wize Pharma, Inc. (WIZP), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Wize Pharma, Inc. focuses on the treatment of ophthalmic disorders. This includes dry eye syndrome (DES). The OTCQB-listed Company previously went by the name Star Night Technologies Ltd. It changed its corporate name to Wize Pharma, Inc. in July of 2015. A clinical-stage biopharmaceutical enterprise, the Company is headquartered in Hod Hasharon, Israel.

Wize Pharma has in-licensed certain rights to purchase, market, sell, and distribute a formula named LO2A. This is a drug developed for the treatment of DES, and other ophthalmological illnesses, including conjunctivochalasis (CCH) and Sjögren's Syndrome. Currently, LO2A is registered and marketed by its inventor in Germany and Switzerland for the treatment of DES, in Hungary for the treatment of DES and CCH, and in the Netherlands for the treatment of DES and Sjögren's Syndrome.

Wize Pharma is now conducting a Phase II trial of LO2A for patients with CCH and a Phase IV study for LO2A for DES in patients with Sjögren's. The Company announced in March of last year that it enrolled the initial patient in its Phase IV clinical trial in Israel for LO2A in the symptomatic treatment of dry eye syndrome (DES) in patients with Sjögren's syndrome. This randomized, double-masked study is evaluating LO2A versus Alcon's Systane® Ultra UD, an over-the-counter (OTC) lubricant eye drop product used to relieve dry and irritated eyes.

The design of the study (in addition to meeting marketing approval requirements in Israel) is to support Wize Pharma’s clinical approval pathway for LO2A for the treatment of DES in patients with Sjögren's in other markets including the U.S., China, and Ukraine. LO2A is already approved in Israel for the treatment of DES.

This past November, Wize Pharma announced top line results from its Phase II clinical trial in Israel of LO2A for the symptomatic treatment of dry eye syndrome (DES) in patients with moderate to severe conjunctivochalasis (CCh). Wize Pharma's Chairman, Noam Danenberg, stated, "We are very pleased with these top line results and we look forward to analyzing the full results. We believe the full results from this study, will support our clinical development path and provide firm basis for presentation and discussions with the FDA for the approval pathway of LO2A in the U.S. and additional countries."

Last week, Wize Pharma announced that it signed an agreement with Cannabics Pharmaceuticals, Inc. (OTCQB: CNBX) to form a joint venture (JV) company for researching, developing and administering cannabinoid formulations to treat ophthalmic conditions. Cannabics Pharmaceuticals is a global leader in personalized cannabinoid medicine centered on cancer and its side effects.

This agreement will become effective subject to receipt of an expert opinion, within 30 days from the date of signing, describing the regulatory pathway for eye drops containing cannabinoids.  Upon effectiveness, Wize Pharma shall issue 900,000 shares of its common stock to Cannabics Pharmaceuticals. Cannabics shall issue 2,263,944 shares of its common stock to Wize. This agreement will expire if the parties have not approved a business plan by June 30, 2019.

Wize Pharma, Inc. (WIZP), closed Monday's trading session at $0.80, down 0.99%, on 2,400 volume with 1 trade. The average volume for the last 3 months is 3,735 and the stock's 52-week low/high is $0.28/$6.09.

chart

Elixinol Global Limited (ELLXF)

Penny Stock Hub, Proactive Investors, Stock Target Advisor, Market Screener, TradingView, New Cannabis Ventures, Stockhouse, Morningstar, Dividend Investor, InvestorsHub, Barchart, MarketWatch, 4-Traders, and Wallet Investors reported previously on Elixinol Global Limited (ELLXF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Elixinol Global Limited is an international company operating in the industrial hemp, dietary supplements, as well as emerging medicinal cannabis sectors. The Company, through its businesses, has a global presence in the cannabis industry. This includes hemp-derived CBD dietary supplements, hemp food and wellness products, and the cultivation and manufacture of medicinal cannabis products. OTCQX-listed, Elixinol Global has its corporate headquarters in Sydney, Australia.

The Company’s businesses include Elixinol USA, Hemp Foods Australia, and Elixinol Australia. Elixinol USA (established in 2014) is a manufacturer and global distributor of industrial hemp based dietary supplement and skincare products. Elixinol USA has operations based out of Colorado. Elixinol USA is a CBD-based dietary supplements products business. It has products now selling in the United States and 40 countries.

Hemp Foods Australia (established in 1999) is a foremost hemp food wholesaler, retailer, manufacturer and exporter of bulk and branded raw materials, and finished products. Hemp Foods Australia is the largest hemp foods provider in Australia. Elixinol Australia was created in 2014 to participate in the emerging Australian medicinal cannabis market. It has applications pending for cultivation and manufacturing licenses.

Last month, Elixinol Global announced its entry into the New Zealand marketplace. The Company is offering its complete range of cannabidiol (CBD) products to the New Zealand public on a prescription basis by way of the elixinol.com website.

Colorado-based Elixinol, the wholly-owned subsidiary of Australian-headquartered Elixinol Global, launched in New Zealand following the December 2018 passage of New Zealand’s Misuse of Drugs (Medicinal Cannabis) Amendment Act. This Act classifies CBD with low levels of THC (the main psychoactive constituent of cannabis) as prescription medicine and removes CBD as a Class B1 controlled drug. The Act recognizes CBD as a substance with “therapeutic value with little or no psychoactive properties”.

Subsidiary Elixinol has expanded its EU (European Union) operations with key personnel hires and offices in the Netherlands, Spain, and the United Kingdom (UK). These appointments are accompanied by a new go-to-market strategy and important initiatives. These include the launch of new e-commerce capabilities, sales hubs, with 12 full-time sales and marketing employees, in the Netherlands, Spain, and the UK targeted at capturing the European cannabis market opportunity.

Elixinol Global Limited (ELLXF), closed Monday's trading session at $2.18, down 4.39%, on 383,872 volume with 445 trades. The average volume for the last 3 months is 339,326 and the stock's 52-week low/high is $0.95/$2.59.

chart

Beleave, Inc. (BLEVF)

NetworkNewsWire, Research Pool, TradingView, Marketwired, Penny Stock Tweets, OTC Markets, New Cannabis Ventures, Equities, MarketWatch, Morningstar, 4-Traders, Midas Letter, Daily Marijuana Observer, Weed Newswire, Wallet Investor, The Street, InvestorsHub, Business Insider, Investing News, Cannabis Newswire, Investors Hangout, Stockhouse, Barchart, and Primed Equities reported previously on Beleave, Inc. (BLEVF), and we report on the Company as well, here at the QualityStocks Daily Newsletter.

Beleave, Inc. is a diversified biotechnology company with a purpose-built ACMPR licensed cannabis facility near Hamilton, Ontario. Additionally, the OTCQX-listed Company has patient services clinics operating throughout Ontario under the Medi-Green brand. Its wholly-owned subsidiary is Beleave Kannabis Corp. Beleave earlier closed on the acquisition of the Medi-Green Cannabis Clinic Network. London, Ontario is Beleave’s fourth clinic joining three Ontario locations already open in Hamilton, Kingston, and Perth. Beleave is headquartered in Oakville, Ontario.

Beleave has developed water-soluble cannabis-infused powder and sugar products to prepare for the adult recreational cannabis-infused food and beverage market in 2019. Its Hamilton, Ontario laboratory is undergoing expansion to make room for methods to formulate cannabis extracts into soluble, flavorless powders, sugar crystals, and syrups for use in beverages and food products using stability-enhancing techniques for prolonged shelf-life.

The Company’s aim is to provide a consistent, reliable and standardized product to suit the needs of every person. Beleave concentrates on green initiatives. It grows its plants using no pesticides. Furthermore, its facilities host a large-scale, commercial, solar installation that substantially offsets its carbon footprint. Beleave’s water supply is on a closed loop system to recycle every drop.

Beleave’s products include Shishkaberry, CBD god bud, and Cold Creek Kush. Shiskaberryʼs buds have a fruit and berry aroma with shades of purple. CBD god bud was created by mixing an almost pure Sativa strain named Hawaiin with a very strong purple Indica strain. Cold Creek Kush is an Indica-dominant hybrid. It crosses the strong MK Ultra and Chemdawg 91.

In July of 2018, Beleave announced the acquisition of 100 percent of the outstanding shares of Seven Oaks, Inc. This acquisition follows important news of Seven Oaks branded cannabis products being chosen by Manitoba Liquor and Lotteries Corporation and the BC Liquor Distribution Branch for sale to consumers in deals expected to produce initial revenues of more than $2,900,000. Beleave will offer Seven Oaks-branded cannabis flower, pre-rolls, and oils.

Beleave announced this past November that it secured genetics acquisition agreements for a broad assortment of cannabis seed varieties from different lineages. There will be 90 new varieties introduced in 2019. These have been selected to cover the entire spectrum of low, intermediate, and high THC and CBD profiles.

In January of this year, Beleave announced that its wholly-owned subsidiary Beleave Kannabis was authorized by Health Canada to sell cannabis oil products effective January 11, 2019. After reviewing the application and supporting documentation, Health Canada granted an amended license with modified conditions allowing for the sale of cannabis oil under the Cannabis Regulations.

Beleave, Inc. (BLEVF), closed Monday's trading session at $0.08396, down 5.13%, on 385,551 volume with 65 trades. The average volume for the last 3 months is 412,043 and the stock's 52-week low/high is $0.05/$0.2836.

chart

Cocrystal Pharma, Inc. (COCP)

Microcapmillionaires, Stock Twits, Tip Ranks, YCharts, Street Insider, Proactive Investors, MarketWatch, Stockwatch, Simply Wall St, Business Wire, Seeking Alpha, Promotion Stock Secrets, Wall Street Resources, The Street, Stockhouse, Penny Stocks Forever, GuruFocus, Equity Clock, Market Screener, Barchart, and Investors Hub reported previously on Cocrystal Pharma, Inc. (COCP), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.

Cocrystal Pharma, Inc. develops novel antiviral therapeutics as treatments for serious and/or chronic viral diseases. The Company uses unique technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs. The design of these technologies, including its nucleoside chemistry expertise and market-centered approach to drug discovery, are to efficiently deliver small molecule therapeutics, which are safe, effective, and convenient to administer. A biotechnology enterprise, Cocrystal Pharma is headquartered in Bothell, Washington.

The Company’s proprietary technologies revolve around a structure-based drug discovery strategy teamed up with extensive nucleoside experience. Utilizing techniques called protein cocrystallization and X-ray crystallography, Cocrystal Pharma quickly identifies novel binding sites, identifies critical inhibitor-protein interactions, and optimizes the structure of the inhibitor in a highly rapid iterative fashion. The Company has identified promising, preclinical stage antiviral compounds for unmet medical needs. These include hepatitis, influenza, and norovirus infections.

Cocrystal is developing a series of compounds that are potent non-nucleoside and nucleoside inhibitors of hepatitis C NS5B RNA dependent RNA polymerase, a replication enzyme vital to viral replication and are highly conserved between all hepatitis C genotypes. Therefore, inhibitors of this enzyme are likely to have multi- or pan-genotypic activity.

In addition, the Company is developing compounds that inhibit hepatitis C helicase and NS5A, two enzymes important for viral replication. Cocrystal has also identified a picomolar inhibitor of NS5A; another crucial viral replication protein.

Last month, Cocrystal Pharma announced that it entered into an exclusive license and collaboration agreement with Merck to discover and develop certain proprietary influenza A/B antiviral agents. With this agreement, Merck will fund research and development (R&D) for the program, including clinical development. Merck will be responsible for global commercialization of any products derived from the collaboration. Cocrystal Pharma will be paid an undisclosed upfront sum. Cocrystal is eligible to receive payments related to designated development, regulatory and sales milestones with the potential to earn up to $156 million and undisclosed royalties on product sales.

Additionally, last month, Cocrystal Pharma announced safety and preliminary efficacy data for its U.S. Phase 2a study evaluating CC-31244 for the ultra-short treatment of HCV infected individuals. CC-31244 is an investigational, oral, potent, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).

The treatment was well tolerated with no study discontinuations because of adverse events. Eight of 12 subjects achieved the primary efficacy endpoint of sustained virologic response at 12 weeks after completion of treatment (SVR12). SVR12 is defined as undetectable virus in blood 12 weeks after completion of treatment and considered a virologic cure.

Cocrystal Pharma, Inc. (COCP), closed Monday's trading session at $2.65, down 3.64%, on 20,484 volume with 94 trades. The average volume for the last 3 months is 50,595 and the stock's 52-week low/high is $1.51/$6.45.

chart

Greystone Logistics, Inc. (GLGI)

Zacks, Wallet Investor, MicroCapClub, Market Screener, Real Investment Advice, Marketwired, Corporate Information, YCharts, Equity Clock, Capital Cube, Trading View, Stockhouse, last10k, Stockopedia, InsiderWisdom, GuruFocus, NoNameStocks, Morningstar, Simply Wall St, and MarketWatch reported previously on Greystone Logistics, Inc. (GLGI), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Greystone Logistics, Inc. reprocesses and sells recycled plastic. In addition, the Company designs, manufactures, sells, and leases high-quality 100 percent recycled plastic pallets. These provide logistical solutions required by a broad variety of industries. These industries include food and beverage, agricultural, automotive, chemical, and pharmaceutical and consumer products. A "Green" manufacturing and leasing business, Greystone Logistics is headquartered in Tulsa, Oklahoma.

Greystone Logistics is the largest 100 percent recycled plastic pallet manufacturer in the U.S. The Company provides cost advantages over users of virgin resin. The excess plastic not used in the production of pallets undergoes reprocessing for resale.

Greystone’s products include rackable, nestable, display, monoblock, and stackable pallets. Furthermore, its products include picture frame web-top pallets and web-top pallets. The Company also sells recycled plastic that undergoes reprocessing into pellet form. Moreover, Greystone provides pallet leasing services.

Greystone Logistics offers recycled pallets for sale including full picture frame and three skids models and IBC pallets. Plastic pallets last 10-50 times longer than wood; have trade-in value; are recyclable; have a high coefficient of friction with anti-skid design for top, bottom, and fork lift tine contact; have substantially lower life cycle costs (cost per trip) and are suited for closed loop systems.

Greystone’s technology, including that used in its injection molding equipment, and its proprietary blend of recycled plastic resins and patented pallet designs, enables fast production of high-quality pallets and at lower costs than numerous processes. The recycled plastic for its pallets helps control material costs, while reducing environmental waste.

Last month, Greystone Logistics reported continued record sales for the six months and quarter ended November 30, 2018. Sales for the six months ended November 30, 2018 were $32,939,240 compared to $20,009,177 for the six months ended November 30, 2017 for an increase of $12,930,063. This represents a 65 percent increase.

Sales for the three months ended November 30, 2018 were $14,733,130 versus $9,722,102 for the three months ended November 30, 2017. This represents an increase of $5,011,028, a 52 percent increase. The Company’s sales to major customers during the six months ended November 30, 2018 were 84 percent of sales versus 73 percent in the same period last year.

Greystone Logistics, Inc. (GLGI), closed Monday's trading session at $0.535, down 6.14%, on 2,700 volume with 2 trades. The average volume for the last 3 months is 7,735 and the stock's 52-week low/high is $0.378/$0.771.

chart

Marfrig Global Foods S.A. (MRRTY)

Market Screener, OTC Markets, Morningstar, Glitch Traders, The Street, MarketWatch, InvestorsHub, YCharts, Research Pool, Capital Cube, Investing, Seeking Alpha, GuruFocus, and Dividend Investor reported on Marfrig Global Foods S.A. (MRRTY), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.

Marfrig Global Foods S.A. is a multinational company operating in the food and food service industries in Brazil and around the world. The Company’s activities include the production, processing, further processing, sale and distribution of animal proteins and a variety of other food products. These include breaded products, ready-to-eat meals, fish, frozen vegetables and desserts, among others.

Established in 1986, the Company formerly went by the name Marfrig Alimentos S.A. It changed its name to Marfrig Global Foods S.A. in January 2014. Marfrig Global Foods has its head office in São Paulo, Brazil.

Marfrig Global Foods currently operates 23 processing units, 12 further processing units and eight distribution centers spread across Brazil, Argentina, Uruguay, Chile and the United States. The Company has leadership in two of the world’s largest beef markets. It has its products in approximately 100 countries.

Marfrig operates through its Marfrig and National Beef divisions. The Marfrig Beef business unit is an innovator in marketing and promoting beef and lamb in the Brazilian marketplace. International operations in South America concentrate on exporting premium beef cuts and on taking advantage of the strategic position the Company has in Uruguay that gives Marfrig Beef access to the world’s important consumer markets.

Last year, Marfrig acquired control of National Beef, which is the fourth largest U.S. beef processor. Headquartered in Kansas City, Missouri, National Beef owns two processing plants. National Beef has a slaughtering capacity of 12,000 cattle heads per day.

In North America, Marfrig Global Foods is responsible for the primary processing and deboning of beef cattle originating from the United States. These products sell internally by way of retail, wholesale and food service channels as well as exported to different markets. Moreover, the business includes the sale of ancillary/complementary products and sub-products resulting from the process, the tannery and logistics operations and direct online sales to consumers.

Marfrig Global Foods S.A. (MRRTY), closed Monday's trading session at $1.54, up 1.99%, on 10,350 volume with 22 trades. The average volume for the last 3 months is 9,808 and the stock's 52-week low/high is $1.19/$2.69.

chart

StrikeForce Technologies, Inc. (SFOR)

The OTC Reporter, Capital Cube, Stockhouse, Silicon Investors, Insider Financial, Simply Wall St, Investing, Stockopedia, Tip Ranks, OTC Markets, MarketWatch, Penny Stock Tweets, Barchart, YCharts, GuruFocus, Morningstar, Investors Hangout, InvestorsHub, Street Insider, and Nasdaq.com reported earlier on StrikeForce Technologies, Inc. (SFOR), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

StrikeForce Technologies, Inc. provides strong two-factor, “Out-of-Band” authentication, and keystroke encryption along with mobile solutions. The Company helps to prevent Cyber theft and data security breaches for consumers, corporations, and government agencies. OTCQB-listed, StrikeForce Technologies is headquartered in Edison, New Jersey. BlockSafe Technologies is a subsidiary company of StrikeForce Technologies.

StrikeForce’s three chief products are ProtectID® (authentication), MobileTrust® (mobile device application), and GuardedID® (keystroke encryption). ProtectID® has an array of potential authentications methods. These methods include Out-of-Band Phone; Out-of-Band Push; Hard Tokens; Mobile Tokens; as well as Desktop Tokens.

GuardedID® stops malicious keylogging programs. It does so through encrypting keystroke data and routing it directly to one’s internet browser or desktop via a secure pathway that is invisible to keyloggers. MobileTrust® eliminates the threat from keylogging hackers. It does so through preventing them from detecting ones’ keystrokes.

StrikeForce provides the above-mentioned “Out-of-Band Authentication” and “Endpoint Protection” utilizing keystroke encryption, for signing on securely to one’s bank, broker, retail stores, and more. Also, the Company provides mobile device security on one’s Apple or Android devices.

The Company’s BlockSafe Technologies subsidiary centers on providing security solutions to protect blockchain and cryptocurrencies. BlockSafe Technologies will offer three innovatively redesigned security solutions. The first is Blockchain Defender™. The Company states that this will be the industry’s most completely dedicated Blockchain firewall. The other two solutions are Desktop Defender™ and Mobile Defender™. These two products will protect digital wallets and cryptocurrencies on MS Windows, Apple, iOS, and also Android platforms.

Last month, StrikeForce Technologies and Caroni Solutions, LLC announced the official Ecuadorian and South American product launch of StrikeForce Technologies ProtectID®.

Andrés Merino, South America spokesperson for Caroni Solutions, said, "We're excited to partner with industry leader StrikeForce Technologies to deliver the industry's most versatile, flexible and cost-effective multi-factor Out-of-Band authentication platform. ProtectID® is an affordable, flexible, and redundant authentication technology that Ecuador's banks, corporations, universities, and government agencies need to protect their networks and customers."

StrikeForce Technologies, Inc. (SFOR), closed Monday's trading session at $0.01535, down 2.23%, on 7,740,581 volume with 69 trades. The average volume for the last 3 months is 3,073,262 and the stock's 52-week low/high is $0.0065/$0.0255.

chart

Noble Roman’s, Inc. (NROM)

TaglichBrothers, Marketbeat, FeedBlitz, The Bowser Report, StockOodles, Wall Street Resources, and SmallCapVoice reported on Noble Roman’s, Inc. (NROM), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Noble Roman's, Inc. sells and services franchises and licenses for non-traditional foodservice operations and stand-alone take-n-bake locations. The Company’s business model consists of three growth venues. These are Grocery Take-n-Bake Licensing; Non-Traditional Franchising; and Stand-Alone Franchising. OTCQB-listed, Noble Roman’s has its corporate office in Indianapolis, Indiana.

The Company franchises and licenses under the Noble Roman’s Pizza, Noble Roman’s Take-N-Bake, Tuscano’s Italian Style Subs, and Noble Roman's Craft Pizza & Pub (CPP) trade names.  Noble Roman’s has awarded franchise and/or license agreements in all 50 U.S. States plus Washington, D.C. In addition, it has awarded franchise and/or license agreements in Canada, Puerto Rico, the Bahamas, Italy, and the Dominican Republic.

Concerning Stand-Alone Venues, these are traditional pizzeria locations and Take-n-Bake locations. There is a merging over time between the kinds of Stand-Alone Venues: Live Yeast Dough; Hand-Rolled Breadsticks; and Baking Services.

Grocery Take-n-Bake Licensing involves licensing to sell Noble Roman’s Pizza. This is a component program using Noble Roman’s ingredients, in which delis assemble pizzas from standard Noble Roman’s ingredients.

Regarding Non-Traditional Venues, these are usually located in a host facility whose principal business is other than foodservice. These facilities can add pizza-focused foodservice as a Revenue Center; as a Facility Draw; and as an Employee Benefit.

The first Noble Roman's Craft Pizza & Pub (CPP) opened on January 31, 2017 in Westfield, Indiana in the Monon Marketplace on Main Street/Highway 32 across from Grand Park.

Recently, Noble Roman's announced it opened a fourth location of its new-generation, stand-alone pizzeria concept, Noble Roman's Craft Pizza & Pub. The newest location is in Carmel, Indiana on Main Street just east of Meridian Street/US 31N.

Also recently, Noble Roman's announced it awarded a franchise to Patrick and Holly O'Neil for a location in Tippecanoe County that includes Lafayette and West Lafayette, Indiana. The O'Neil's are experienced multi-unit foodservice operators and Dairy Queen's largest franchisee in Indiana, with 19 locations in Indiana.

During the three-month and six-month periods ended June 30, 2018, Total Revenue from Noble Roman’s four company-owned and operated Craft Pizza & Pub  locations were $1.2 million and $2.4 million, respectively. Total Expenses for the Craft Pizza & Pub locations for the three-month and six-month periods ended June 30, 2018 were $964,000 and $1.8 million, for an operating profit of 22.6 percent and 22.4 percent for the three-month and six-month periods.

Noble Roman’s, Inc. (NROM), closed Monday's trading session at $0.495, up 2.06%, on 2,000 volume with 1 trade. The average volume for the last 3 months is 19,146 and the stock's 52-week low/high is $0.33/$0.87.

chart

Optex Systems Holdings, Inc. (OPXS)

OTCMagic, Damn Good Penny Picks, Penny Picks, PennyStockLocks, Prepump Stocks, StockRockandRoll, Stock Beast, Penny Stock Newsletter, Stock Commander, MicroCapDaily, Epic Stock Picks, Wolf of Penny Stocks, DSR News, DamnGoodPennyStock, PHUB News, William Velmer, and S.A. Advisory reported on Optex Systems Holdings, Inc. (OPXS), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Optex Systems Holdings, Inc. is a top manufacturer of optical sighting systems and assemblies, chiefly for Department of Defense (DoD) applications. In addition, the Company manufactures and delivers multiple periscope configurations, rifle and surveillance sights, and night vision optical assemblies. Optex delivers its products directly to the military services and to prime contractors. OTCQB-listed, Optex Systems Holdings has its corporate office in Richardson, Texas.

Optex Systems, Inc. is a wholly-owned subsidiary of Optex Systems Holdings. Optex Systems Holdings reported in November 2014 the completion of the acquisition of the Applied Optics Center (AOC) Division of Warrior Systems Sector with the Electronics Systems Business Segment of L-3 Communications Corp.

Optex Systems’ products are installed on diverse kinds of U.S. military land vehicles. These include the Abrams and Bradley fighting vehicles, Light Armored and Armored Security Vehicles. Additionally, the Company’s products have been chosen for installation on the Stryker family of vehicles.

Optex Systems manufactures the US Navy 20x 120mm Ship Binoculars. Moreover, the Company brings creative technology to vehicular mounted sighting systems. Its dismounted sighting systems work on weapon sights, night vision goggles, and any other sighting requirements outside of ships and land vehicles. Furthermore, Optex Systems can meet commercial (non-military) requirements.

Optex Systems, Inc. announced this past March that it was awarded $1.62 million as part of a multi-year strategic supplier agreement with a domestic manufacturer of first-class optical devices. The products will be manufactured at the Applied Optics Center (AOC) Division of Optex Systems, Inc. AOC is a vital supplier of technically challenging thin-film coatings, optical components, assemblies and systems.

Optex Systems Holdings financial highlights from its Q2 2018 financial results were solid. During the three and nine months ending July 1, 2018, the Company has experienced considerable Revenue growth of 41.9 percent and 30.3 percent, respectively, versus the three and nine months ending July 2, 2017.

It also experienced improvements in Gross Margin percentages of 4.2 percent and 3.0 percent and reductions in its General and Administrative Expenses of 5.8 percent and 6.9 percent, respectively, versus the three and nine months ending July 2, 2017.

Optex Systems Holdings, Inc. (OPXS), closed Monday's trading session at $1.82, up 4.00%, on 28,315 volume with 21 trades. The average volume for the last 3 months is 17,816 and the stock's 52-week low/high is $0.93/$1.88.

chart

Gopher Protocol, Inc. (GOPH)

Profitable Trader Authority, Wall Street Mover, PennyStockScholar, PennyTrader, OTCtipReporter and Integrity Solution IR reported on Gopher Protocol, Inc. (GOPH), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

Gopher Protocol, Inc. is developing Internet of Things (IoT) and Artificial Intelligence (AI) enabled mobile technology. The Company provides a mobile technology for computing power enhancement, advanced mobile database management/sharing, and additional features. Its Integrated Circuit (IC), named GopherInsight™, and accompanied software, creates a private and secured network for sharing information and adapting to user preferences. The system is self-learning and always developing. OTCQB-listed, Gopher Protocol is headquartered in Santa Monica, California.

The Company is developing a real-time, heuristic based, mobile technology. Upon development, the mobile technology will consist of a smart microchip, mobile application software, and supporting software, which run on a server. The system envisions the creation of an international network. The heart of this system will be its advanced microchip that will be able to undergo installation in any mobile device.

Gopher Protocol’s expectation is that this will result in an internal, private network between all mobile devices using the device through providing mobile technology for computing power enhancement, advanced mobile database management/sharing, and more mobile features.

Gopher Protocol has its licensed technology, the Guardian Patch. The Guardian Patch device was conceived as an offshoot of its microchip technology named GopherInsight™. The mobile tracking technology will track and protect anything one cares about, with or without GPS (Global Positioning System). The Guardian Patch is a stick-on tracking device.

Additionally, the Company has its "dDrone" technology. This technology utilizes Artificial Intelligence (AI) to create what is believed to be the world's first" Smart Drone." Gopher AI drone technology employs machine learning to give drones advanced flight capabilities.

Gopher Protocol is working to integrate its Guardian Patch radio technology within its digital coin Blockchain system. Recently, the Company was granted its Guardian Patch patent and filed a non-provisional patent for its cryptocurrency system. Gopher Protocol’s exclusive licensor filed a non-provisional patent encompassing a proprietary GRC Blockchain-Based Radio Generated Digital Currency as announced on June 19, 2018.

The GRC, designed to be a new generation of cryptocurrency, will be using the Guardian Patch System to perform transactions and operations. In this way, each Guardian Patch user will have the option to use the GRC when using the Guardian Patch.

Gopher Protocol is incorporating its gEYE security engine into its digital currency Technology Platform, the GRC. With Gopher technology, upon full development, the radio based coin will provide that each transaction, called a block, is recorded. The gEYE system goal will be to secure Gopher's gNET communication protocol. The gEYE includes multiple layers of security methods. This includes advanced encryption.

Gopher Protocol, Inc. (GOPH), closed Monday's trading session at $0.41, up 5.13%, on 489,290 volume with 176 trades. The average volume for the last 3 months is 399,681 and the stock's 52-week low/high is $0.289/$4.85.

chart

Nippon Dragon Resources, Inc. (RCCMF)

Stock Gumshoe, OTC Markets Group, InvestorPlace, Stockhouse, Talk Markets, Streetwise Reports, and 4-Traders reported previously on Nippon Dragon Resources, Inc. (RCCMF), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter

Nippon Dragon Resources, Inc. is a hybrid mining & technology enterprise. The Company has high potential and advanced stage mining assets combined with a unique and exclusive green mining method. Nippon is active in the exploration and development of gold resources in the Province of Quebec. OTCQB-listed, Nippon Dragon Resources has its corporate office in Brossard, Quebec.

Nippon has its Thermal Fragmentation mining method. This is a mining method that uses heat to 'spall' high-grade veins, considerably decreasing the use of explosives. The method only extracts the mineralized ore with minimal dilution. The extraction process permits thermal fragmentation with an accuracy of 2 cm to rapidly extract any type of hard rock up to 110 cm wide.

With this precision, high grade precious and base metal veins can undergo extraction without dilution. The thermal unit can be set up to extract a specific corridor. Thermal Fragmentation could be utilized as a stand-alone method or as a first-rate complement to any conventional hard rock mining operation.

Nippon’s flagship gold property is Rocmec 1. This is a fully permitted project in Quebec. The project includes a 100-meter deep, two-compartment shaft, and an 844 meters’ decline, allowing access to four levels (50, 90, 110 and 130 meters).

The Company also has its Courville-Maruska exploration property in Courville Township, about 32 kilometers’ northeast of Val-d'Or, Quebec. The property comprises 20 mining claims encompassing an area of roughly 800 hectares. The property is on a gold-bearing quartz vein system.

Furthermore, Nippon has its Denain Project. This project covers two contiguous mining properties (Venpar and Vauquelin) totaling 24 mining titles. The Denain Project is around 60 km east of Val d'Or, Quebec.

Nippon Dragon Resources has a strategic partnership agreement with Val d’Or Resources (VOR). The partnership agreement will enhance Nippon Dragon’s position as an industry leader with its exclusive and patented Thermal Fragmentation technology. Via the creation of a new entity, Rocmec Gold, Inc., the new partnership is expected to substantially expand Nippon Dragon’s reach within Canada and other important markets.

Recently, Nippon Dragon Resources announced that following the sale of a thermal fragmentation unit to its client, Metalfer Mining D.O.O, the Unit was shipped, received, inspected by border authorities and released to the client. In June, Nippon’s technical team started its customary four week orientation, training and implementation programme of its thermal fragmentation mining method at Metalfer’s mining site in Majdan Mountain district of Serbia.

Metalfer chose four of its employees with mechanical and heavy equipment experience to be trained to operate the Unit. This training programme covers all elements related to safety issues, hands-on instructions, operational usage, production and servicing of the Unit.

Nippon Dragon Resources, Inc. (RCCMF), closed Monday's trading session at $0.0181, up 98.90%, on 14,500 volume with 3 trades. The average volume for the last 3 months is 14,987 and the stock's 52-week low/high is $0.002/$0.05.

chart

Hochschild Mining PLC (HCHDF)

Zacks, YCharts, Stockhouse, The Street, 4-Traders, Dividend Investor, Wallet Investors, and OTC Markets reported on Hochschild Mining PLC (HCHDF), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.

Hochschild Mining PLC engages in the exploration, mining, processing, and sale of silver and gold deposits in the Americas. A precious metals enterprise, the Company is a leading underground precious metals producer focusing on high grade silver and gold deposits.

Hochschild Mining is headquartered in Lima, Peru. The Company also has a corporate office in London, United Kingdom (UK) and an office in Argentina.

Hochschild Mining currently operates four underground mines. Three are in southern Peru and one is in southern Argentina.  All of the Company’s underground operations are epithermal vein mines. The primary mining method used is cut and fill. The ore at Hochschild’s operations is processed into silver-gold concentrate or dore.

Regarding present operations, Inmaculada is the Company’s flagship asset. Inmaculada is a 20,000 hectare two-third gold and one-third silver mine consisting of 40 mining concessions located in the Ayacucho Department in southern Peru.

The Arcata unit is situated in the Department of Arequipa in southern Peru. It is approximately 300 kilometers from the city of Arequipa, on a 47,000-hectare site. Arcata is a 100 percent owned underground operation.

The Pallancata silver/gold property is positioned in the Department of Ayacucho in southern Peru, roughly 160 kilometers from the Arcata operation. Pallancata commenced production in 2007. Hochschild Mining owns 100 percent of the operation.

The San Jose silver-gold mine is in Argentina, in the Santa Cruz province, 1,750 kilometers south-southwest of Buenos Aires. The property covers a total area of 50,491 hectares. The property consists of 46 contiguous mining concessions totaling 40,499 hectares and an exploration permit covering almost 10,000 hectares.

Last month, Hochschild Mining announced that it delivered a new record half of attributable production with 268,237 gold equivalent ounces or 19.9 million silver equivalent ounces chiefly driven by considerable increases at Inmaculada and Pallancata, and another strong result from the 51 percent owned San Jose mine.

Hochschild reiterates that its all-in sustaining cost (AISC) for 2018 is on course to be $960-$990 per gold equivalent ounce ($13.0-13.4 per silver equivalent ounce).

Regarding Brownfield exploration at Inmaculada, in Q2 Hochschild Mining continued its wide-ranging drilling programme with encouraging results indicating significant additions to the deposit's resource base close to the existing mine infrastructure. The focus of the present campaign is to the east of the Angela vein with close to 20,000m of resource drilling carried out in Q2 centered on the Millet, Divina, Lola and Lizina veins.

Hochschild Mining PLC (HCHDF), closed Monday's trading session at $2.50, up 1.71%, on 10,800 volume with 2 trades. The average volume for the last 3 months is 4,635 and the stock's 52-week low/high is $1.96/$3.31.

chart

BioVie, Inc. (BIVI)

Wealth Insider Alert reported previously on BioVie, Inc. (BIVI), and today we report on the Company, here at the QualityStocks Daily Newsletter.

BioVie, Inc. focuses on the discovery, development, and commercialization of inventive drug therapies for liver disease. Currently, the clinical-stage Company is concentrating on commercializing BIV201. This is a novel approach to the treatment of ascites due to chronic liver cirrhosis. BioVie has its corporate headquarters in Beverly, Massachusetts. The Company’s shares trade on the OTCQB.

BIV201 is a continuous infusion of the peptide terlipressin, first undergoing development for the treatment of refractory ascites. Terlipressin, dosed differently, is approved in approximately 40 nations for other complications of liver cirrhosis coming up from a similar disease pathway. Terlipressin is not available in the United States.

BioVie states that BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, NASH, and alcoholism. The US Patent and Trademark Office (USPTO) issued US Patent No. 9,655,945 covering the Company’s new drug candidate BIV201.

BIV201 has Orphan Drug designation for the most common of these complications, ascites, which represents a major unmet medical need. The FDA has never approved any drug specifically for treating ascites. In addition to patient suffering, U.S. treatment costs for liver cirrhosis, including ascites and other complications, are estimated at over $4 billion per year.

In April 2017, BioVie announced that it received notice from the FDA that the planned Phase 2a clinical trial of its new drug candidate BIV201 may begin. This was based on BioVie’s IND to conduct a study in patients with refractory or intractable ascites due to advanced liver cirrhosis.

Furthermore, the Company was notified by the USPTO that its application for a core patent covering the use of BIV201 to lessen ascites formation in ambulatory patients was authorized.

Additionally, BioVie announced in April 2017 the signing of a Cooperative Research and Development Agreement (CRADA). This is to conduct a Phase 2a clinical trial of BIV201 in patients with refractory or intractable ascites because of advanced liver cirrhosis.

In November 2017, BioVie reported that a second patient was dosed with the Orphan drug candidate BIV201 (continuous infusion terlipressin) in a mid-stage Phase 2a clinical trial of patients suffering from refractory ascites due to advanced liver cirrhosis. The design of the study is to evaluate 6 patients with refractory ascites. In October 2017, the first patient completed 28 days of treatment with BIV201 and entered the post-therapy observational period.

Recently, BioVie announced that the FDA granted Fast Track designation for BIV201 (continuous infusion terlipressin), the Company's patented Orphan drug candidate. BIV201 is now undergoing evaluation for the treatment of refractory ascites due to liver cirrhosis in a mid-stage (Phase 2a) US clinical trial, with two of the planned six patients having been treated with this therapy so far. The results for all six refractory ascites patients planned for the Company’s Phase 2a clinical trial of BIV201 are expected by Q2 of 2018.

BioVie, Inc. (BIVI), closed Monday's trading session at $0.038, down 5.00%, on 266,064 volume with 17 trades. The average volume for the last 3 months is 41,278 and the stock's 52-week low/high is $0.012/$0.25.

chart

Newgioco Group, Inc. (NWGI)

OTC Markets, TradingView, MarketWatch, and LAST10K.com reported on Newgioco Group, Inc. (NWGI), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Newgioco Group, Inc. is a betting software technology business. The Company provides regulated leisure lottery and gaming products and services by way of licensed subsidiaries based in Europe. Newgioco Group, together with its wholly-owned subsidiaries, is a fully-licensed and integrated gaming software technology enterprise.

Listed on the OTCQB, Newgioco Group has its headquarters in Toronto, Ontario. The Company also has an office in Rome, Italy. The Company was previously known as Empire Global Corp. It changed its name to Newgioco Group, Inc. in July of 2016.

Newgioco Group conducts its business chiefly through retail neighborhood betting shops and an internet-based gambling and sports betting software platform under the registered brand Newgioco, through its licensed website www.newgioco.it located in Italy.

The Company has acquired Multigioco Srl. This is a licensed gaming operator headquartered in Rome. Newgioco Group’s plan is to aggressively go after attractively priced, fragmented, and profitable gaming operators in Italy. Its goal is to become a top-tier gaming operator over a five-year investment time horizon.

Newgioco provides its clients a comprehensive set of leisure gaming products and services. These include sports betting, virtual sports, online casino, poker, bingo, lottery, interactive games and slots, and an innovative betting platform providing Business-to-Business (B2B) and Business-to-Consumer (B2C) bet processing.

In late January, Newgioco Group announced the signing of four new online gaming operators. This further expands Newgioco's distribution network in Italy.

The four new web skins include www.clubgames.it (Region: Sardegna/Lazio); www.mixbet.it (Region: Campania/Puglia); www.imperialbet.it (Region:Sicilia); and www.quibet.it (Region: Calabria).

The new operators expand Newgioco Group’s fast-growing online distribution to regions not earlier covered by the Company’s webshop locations. This brings the total retail stores to about 1,300. In addition, it increases the number of websites distributing the Newgioco brands to eight.

Recently, Newgioco Group announced the launch of NG PAY payment gateway under a licensing agreement with Euronet Worldwide, Inc. headquartered in Leawood, Kansas. The Company's secure payment gateway by way of Euronet will be available on the www.ngpay.it website. It will make a broad assortment of integrated payment, pre-paid, remittance and reload solutions available to its registered online customers, partners, webshops, and retail stores.

Newgioco Group reported strong transactions growth for Q4 2017. It reported that sport betting volumes in Q4 2017 increased 25 percent on a year-over-year basis to $32 million. Gross gaming profits were $6.5 million in Q4. This is the highest for any quarter in Newgioco’s history. Gross gaming profits increased 82 percent on a year-over-year basis.

Newgioco Group, Inc. (NWGI), closed Monday's trading session at $0.40, up 14.29%, on 11,180 volume with 5 trades. The average volume for the last 3 months is 14,917 and the stock's 52-week low/high is $0.28/$1.78.

chart

The QualityStocks Company Corner

VIVO Cannabis Inc. (TSX.V: VIVO) (OTC: VVCIF)

The QualityStocks Daily Newsletter would like to spotlight VIVO Cannabis Inc. (VVCIF).

VIVO Cannabis Inc. (TSX-V: VIVO, OTCQX: VVCIF) ("VIVO" or the "Company"), a licensed cannabis producer offering premium medical and adult-use products and services, today announces that the Company's subsidiary, ABcann Medicinals Inc. ("ABcann"), has received approval from Health Canada for its most recent license amendment request allowing for the sale of cannabis oil.

VIVO Cannabis Inc. (TSX.V: VIVO) (OTC: VVCIF) is a globally licensed, cost efficient producer of premium quality, organic, standardized medicinal cannabis. One of the earliest licensed medical marijuana producers under Canada’s federally-controlled Access to Cannabis for Medical Purposes Regulations (ACMPR), VIVO has five years of operating experience in the burgeoning medical marijuana space through its flagship operation, ABcann Medicinals, Inc. The company recently received its Health Canada license to produce medical cannabis oils and is working toward production of saleable, extracted, finished products that will lead to a final inspection allowing sales of its oils.

“Receipt of the license to produce cannabis oils is a major milestone in our pursuit to provide our medical cannabis patients with additional product formats that can be precisely dosed. The expansion and innovation of our product lines are a top priority for the Company as we continue to serve the needs of our customers, and we anticipate strong demand for our cannabis oil products,” VIVO CEO Barry Fishman said.

VIVO owns and operates a fully functioning 14,500 square foot facility in Napanee, Ontario, which is being doubled in size to produce 1,400 kg of cannabis per year. The company’s expansion plans include adding a seasonal greenhouse and a hybrid, multipurpose facility, capable of producing 31,000 kg of cannabis per year between the two facilities, to be constructed on 65 acres it already owns near the Napanee facility. This additional location is properly zoned with existing infrastructure in place for an eventual 1.2 million square feet of production space.

VIVO has built a reputation over the years for its best-in-class standardized approach to growing cannabis that includes the absence of pesticides and a computer monitored growing technique that provides a consistent, pharmaceutical-grade with high yields. The company’s custom, scalable growing chambers with proprietary lighting can be replicated anywhere in the world, leading to lower production costs. This technique has helped it record a customer retention rate of 94.7 percent alongside 30 percent month-over-month customer growth. When combined with VIVO’s current yield rate, which it has measured at roughly 100 percent greater than the industry average, the company has constructed a strong foundation upon which to build a sizable presence in the global cannabis industry.

This global growth potential is illustrated by VIVO’s partnership with Israel’s Syqe Medical, producer of the world’s first selective-dose pharmaceutical grade medicinal plant inhaler. After visiting VIVO’s production facility, Perry Davidson, founder of Syqe Medical, noted that the company’s production technologies put it “in a class with the best in the world” in its ability to produce standardized pharmaceutical grade cannabis.

VIVO’s recent acquisition of Harvest Medicine Inc. represents further progress toward the company’s goal of becoming a vertically integrated medical cannabis company. Harvest Medicine is one of the fastest growing medical cannabis clinics in Canada – adding over 1,200 new patients monthly from a single location – with an aggressive expansion plan and a patient-focused approach that perfectly aligns with VIVO’s philosophy of quality and innovation.

VIVO’s seasoned management team, board of directors and advisory board features well over a century of combined industry experience. Fishman, who has over 20 years of experience as a business leader, previously served as CEO of both Teva Canada and Taro Canada, as vice president of marketing at Eli Lilly Canada, and as past chair of the Canadian Generic Manufacturers Association. He most recently served as CEO of international specialty pharmaceutical company Merus Labs.

Notably, VIVO also has access to the ‘Father of Cannabis Research’, Raphael Mechoulam, PhD, through its board of advisors. An organic chemist and professor of medicinal chemistry at the Hebrew University of Jerusalem, Mechoulam was the first scientist to isolate both cannabidiol (CBD) and tetrahydrocannabinol (THC). He has received more than 25 prestigious academic awards, including the Rothschild Prize in Chemical Sciences and Physical Sciences in 2012.

With more than 65 acres of growth capacity, a healthy cash balance to fund upcoming construction efforts, steady sales growth, industry-leading yield rates and an established operations team in place, VIVO is well positioned to compete in the rapidly expanding Canadian cannabis industry and beyond.

VIVO Cannabis Inc. (VVCIF), closed the day's trading session at $0.7019, up 0.91%, on 858,870 volume with 285 trades. The average volume for the last 3 months is 360,140 and the stock's 52-week low/high is $0.413/$2.289.

Recent News

chart

Generation Alpha, Inc. (GNAL)

The QualityStocks Daily Newsletter would like to spotlight Generation Alpha, Inc. (GNAL).

Generation Alpha, Inc. (OTCQB: GNAL), a vertically integrated cannabis company and technology innovator, manufacturer and distributor, is pleased to announce the appointment of international businessman and entrepreneur Mr. David Lenigas to the Board of Directors.

Generation Alpha, Inc. (GNAL) was established in 2010 as a vertically integrated technology innovator, developer, manufacturer and distributor focused on bringing products and solutions to both commercial and individual growers in the United States. Originally named Solis Tek Inc., the company changed its name to Generation Alpha in September 2018 and announced an increased focus on providing innovative and must-have cannabis products and services to a growing industry.

“Generation Alpha for us means ‘new beginning’” said Generation Alpha CEO Alan Lien, when the name change was announced. “It is the new wave of how people and brands connect. We are excited with the transformation of our business strategy, our progress at our Arizona facility and the additional growth opportunities our team has identified elsewhere in the cannabis industry. While we are pleased with our innovation and progress in our Solis Tek lighting and Zelda Horticulture divisions, we believe?Generation Alpha?represents our philosophy of bringing the best cannabis products and services to the market. We are confident that this shift in our business strategy will create long-term shareholder value through diversified segments in the legalized cannabis industry.”

The name change reflects the company’s strategy to leverage business opportunities in different legalized cannabis spaces, including cultivation, processing and retail facilities. As part of that focus, Generation Alpha acts as the holding entity for a collection of companies that bring products and solutions to legal retail and commercial cannabis growers while utilizing its expertise to offer safe, quality and consistent products through its cultivation, processing, and retail facilities as well as branded products in both the medical and recreational markets. Along with its strong focus on the burgeoning cannabis market, Generational Alpha remains committed to developing and providing innovative products and services in both Solis Tek Digital Lighting, its lighting division, and Zelda Horticulture, its agricultural products division.

As part of a key piece of its cannabis focus, Generation Alpha acquired a cannabis cultivation and processing facility in Phoenix, Arizona, which is scheduled to begin operation in 2019. Currently in the design and development stage, the 70,000-square-foot facility will be one of the most technologically advanced cultivation and processing facilities in Arizona, which is a hot bed of cannabis cultivation in North America. Generation Alpha management is confident about the growth and profitability this facility provides as an essential component of its forward-thinking cannabis strategy.

Additional components of this strategy include the company’s GrowPro Solutions, Inc., a nationwide cannabis cultivator and processor and a variety of Generation Alpha brands, which include the innovation, design and selling of cannabis?products such as flower, oils and accessories in the legal medical and recreational markets.

The company’s Zelda Horticulture division offers commercial-grade rolling tables, greenhouses, PH stabilizer and nutrient products, and other agricultural products for cultivators around the world. Zelda’s custom-design cultivation options means its clients can count on increased agricultural productivity and efficiency.

Generation Alpha’s Solis Tek Digital Lighting division offers an extensive line of lighting equipment and accessories, including digital ballasts, reflectors,?complete lighting systems, single- and double-ended digital lamps, controllers and other accessories.?Each product is designed to help retail and commercial growers maximize quality and achieve higher yields and maximize quality.?

Generation Alpha, Inc. (GNAL), closed the day's trading session at $0.69, up 2.99%, on 113,500 volume with 55 trades. The average volume for the last 3 months is 69,148 and the stock's 52-week low/high is $0.289/$1.55.

Recent News

chart

Sharing Services, Inc. (SHRV)

The QualityStocks Daily Newsletter would like to spotlight Sharing Services, Inc. (SHRV).

Sharing Services Inc. (OTCQB: SHRV) will hold a special meeting of shareholders on January 11 for a vote to change its name to Sharing Services Global Corporation (http://nnw.fm/zUJ7h). John “JT” Thatch, CEO of SHRV, said that the name change would more accurately reflect the company’s international expansion moves in 2019. He discussed the company’s strategic growth into Canada and Asia in an interview with www.ProactiveInvestors.com, as seen on YouTube (http://nnw.fm/X9XPv).

Sharing Services, Inc. (SHRV), headquartered in Plano, Texas, is a diversified holdings company focused on reshaping how entrepreneurs succeed today. Sharing Services Inc. owns, operates or controls an interest in a variety of companies specializing in the direct selling industry that either sell products to the consumer directly through independent representatives or offer services that range from health and wellness, energy, technology, insurance services, training, media and travel benefits. SHRV has created the “Blue Ocean Strategy,” which melds three keys together to implement the company’s vision. These keys include elevating home-based entrepreneurs, known as “Elepreneurs,” utilizing the direct selling channel to generate 100 percent organic growth.

Sharing Services Inc. subsidiaries include:

  • A growing international network of home-based entrepreneurs, called “Elepreneurs”
  • Growing selection of health and wellness products dedicated to elevating the well-being of all people
  • Insurance from auto, home and life to health benefit discounts and health insurance that help families elevate their options
  • Wholesale travel and payment programs with travel concierges that empower more families to go on vacation
  • Live seminars and training events – from Vacationars™ to EduTainment – that elevate the skills and knowledge of entrepreneurs around the world
  • Unique compensation and reward programs crafted to help entrepreneurs elevate their health, wealth and happiness

Sharing Services recently expanded its corporate footprint by moving to a 10,000 square foot facility in Plano, Texas, that offers room to expand as the company grows and its subsidiaries flourish. The larger corporate locale provides space for a growing customer service department, product fulfillment, opportunity and training rooms, as well as a video production suite.

“The opportunity to expand to the rest of this new building over the course of the next six to 12 months ensures we won’t have to move again anytime soon,” Sharing Services Inc. Chairman Robert Oblon said. “We are on track for very significant growth here in the U.S., as well as upcoming international expansion, so this move is in preparation for what’s in front of us.”

The company recently signed a joint venture agreement with Health Wealth & Happiness Limited (“HWH”) to expand its “Elepreneurs” brand and market its products throughout Asia. The newly formed company will be named “Elepreneurs Asia Limited” and will have marketing and sales rights to China, Hong Kong, Macau, South Korea, Japan, Taiwan, Cambodia, Indonesia, Laos, Malaysia, the Philippines, Singapore, Thailand, Vietnam and Papua, New Guinea. A soft launch of the Elepreneur program is scheduled sometime later in 2018 with HWH CEP Fai Chan and his team leading the effort. Formed in Hong Kong, Health Wealth & Happiness Limited is dedicated to working with visionary partners like Sharing Services Inc. to deliver the best products and services to improve the well-being of consumers.

Nearly 1,000 people attended Sharing Services, Inc.’s first “Elepreneur Happiness Convention,” held March 2-3, 2018, in Dallas, Texas. Attendees arrived from several countries including the U.S., Canada, Mexico, Singapore and Hong Kong. Keynote speakers included several internationally known motivational leaders – Shawn Achor, Sandra Yancey, John Fleming and Les Brown – who provided exceptional material and inspirational discussion points.

“The enthusiasm of our attendees and the early success that we are experiencing is incredible considering our growth has been 100 percent organic, with almost no marketing from the company,” Oblon said. “I’m speechless by the dedication of our Elepreneur leaders and their entire teams, as they share our incredible line of products that have helped so many people.”

Sharing Services and its management team plan to travel the U.S. to hold several mini conferences to expand on the messages presented at its Happiness Convention that focus on helping people become “healthier, happier and wealthier.” Details of the company’s aggressive global expansion initiatives are soon to be announced, Oblon said.

The law firm of Gardere Wynne Sewell LLP has been retained as outside corporate counsel for all general business matters. The Dallas-based law firm will represent Sharing Services, Inc., and its subsidiaries as the company utilizes the direct selling channel for a significant component of its overall growth strategy.

John “JT” Thatchwas appointed president and chief executive officer of Sharing Services, Inc., at a March 1, 2018, annual shareholder meeting. Thatch has successfully started, owned and operated several sized businesses in various industries. His experience with corporate growth, acquisitions, financing and negotiation in fast-paced and flexible environments will significantly assist Sharing Services Inc. as the company aims to expand and increase revenues.

Sharing Services, Inc. (SHRV), closed the day's trading session at $0.27, up 22.73%, on 507,896 volume with 52 trades. The average volume for the last 3 months is 35,632 and the stock's 52-week low/high is $0.125/$0.589.

Recent News

chart

Spectrum Global Solutions, Inc. (SGSI)

The QualityStocks Daily Newsletter would like to spotlight Spectrum Global Solutions, Inc. (SGSI).

Spectrum Global Solutions,  Inc. (OTCQB: SGSI), a multi-national single-source provider of next-generation communications network professional services and software solutions to telecommunications and enterprise markets, announced today that it was able to utilize an equity investment received in connection with the previously reported merger with WaveTech Global of approximately $1.1 Million to satisfy the debt owed to Libertas Funding LLC, (“Libertas”) that was incurred in connection with the Company’s acquisition of TNS.

Spectrum Global Solutions, Inc. (SGSI) is a leading single-source provider of end-to-end, next-generation wireless and wireline network infrastructure services and staffing solutions to the service provider (carrier) and corporate enterprise markets across the United States, Canada, Puerto Rico, Guam and the Caribbean. Spectrum Global Solutions provides services directly to carriers, aggregators, utilities, enterprise, Project Management Organizations (PMO) and Original Equipment Manufacturers (OEM) clientele through the following subsidiaries:

  • AW Solutions, Inc. and AW Solutions Puerto Rico, LLC – Provides best-in-class communications infrastructure deployment services to carriers, OEMs, PMOs, utilities and enterprise clients by offering discrete and full turnkey service solutions for wireless and wireline clientele. AW Solutions holds professional engineering licenses in all contiguous states and in the District of Columbia and Hawaii; the Canadian provinces of British Columbia, Quebec, Ontario, Alberta and Newfoundland and Labrador; in Puerto Rico, Guam and the U.S. Virgin Islands.
  • ADEX Corporation and ADEX Puerto Rico, LLC – An international service organization providing turnkey services and staffing solutions to telecommunications carriers and enterprise clients. Since 1993, ADEX has been assisting telecommunications companies throughout the project life cycle of any network deployment. ADEX and its service capabilities extend from the most basic installation functions to the most advanced engineering disciplines for today and tomorrow’s communications networks. Headquartered in Atlanta, Georgia, ADEX employs technical professionals and provides infrastructure services worldwide via domestic and international locations.
  • Tropical Communications, Inc. – A state licensed electrical and underground utility contractor headquartered in Miami, Florida, providing all types of communications and infrastructure facility structured wiring services and solutions since 1984.

Through its subsidiaries, Spectrum Global Solutions is a comprehensive single-source provider for professional services and solutions for the development, deployment and maintenance of wireless/Distributed Antenna System (DAS)/small cell/wireline and fiber networks and infrastructure. The company’s services range in scope from a single activity to multiyear, multi-region, large-scale turnkey development contracts with a deepening pool of international, national, regional and local projects. Spectrum Global Solutions has completed more than 150,000 project activities on wireless, DAS, wireline and fiber networks across the United States utilizing licensed professional engineers, project managers, technicians and general contractors.

Market Opportunity

Growth projections for the telecom industry show a high growth cycle 2018 through 2025 with a four-fold increase in domestic mobile data traffic and up to $150 billion in fiber investment over the next 5-7 years (Deloitte, 2017). The worldwide explosion of smart phones, tablets and BYOD by customers demanding rapid deployment of new apps, private networks with better coverage and enhanced capacity provides a compelling enterprise opportunity market. The imminent rollout of 5G next generation networks, IOT (Internet-Of-Things) technology deployments, the FirstNet national public safety system, small cell/network densification, Dish Network Deployment, fiber and infrastructure network builds for backhaul and expanded deployments, new FCC spectrum auctions and upgrades to 4G, DAS and small cell networks are contributing to a projected $157 billion in U.S. telecommunication carrier capital expenditures by 2021.

Management

CEO Roger Ponder has served as a director of Spectrum Global Solutions since April 2017. Ponder served as President/CEO of Summit Capital Advisors, LLC, and Summit Broadband, LLC a provider of consulting services to private equity and institutional banking entities in the telecommunications, cable and media/internet sectors. He also served as a member of the board of directors of InterCloud Systems, Inc. and served as its Chief Operating Officer from November 2012 to March 2015. Prior to that Ponder retired from Time Warner Kansas City Division as President/CEO. Ponder brings extensive business development, strategic planning and operational experience to the Company.

Keith Hayter is President of Spectrum Global Solutions and has served as a director of the Company since April 2017. Hayter has also served as the Chief Executive Officer and President of AW Solutions Inc. and AW Solutions Puerto Rico LLC since November 2006. He was Vice President and General Manager of Alcoa Wireless Services from 2001-2006. Hayter served in both the U.S. and British armies and brings extensive multi-national experience in the start-up, development, management and growth of companies in the telecommunication, engineering and construction industry.

Spectrum Global Solutions, Inc. (SGSI), closed the day's trading session at $0.265, up 1.92%, on 158,305 volume with 44 trades. The average volume for the last 3 months is 32,658 and the stock's 52-week low/high is $0.0813/$2.59.

Recent News

chart

BriaCell Therapeutics Corp. (OTC: BCTXF) (TSX.V: BCT)

The QualityStocks Daily Newsletter would like to spotlight BriaCell Therapeutics Corp. (BCTXF).

According to a report published in the British Society of Immunology, a new era has begun in the battle against cancer, as the development of immunotherapies for malignancies will take cancer treatments to a whole new level (http://nnw.fm/0MseG). Several companies, including BriaCell Therapeutics Corp. (OTCQB: BCTXF) (TSX.V: BCT), are leading the way.

BriaCell Therapeutics Corp. (OTC: BCTXF) (TSX.V: BCT), based in Berkeley, CA, and headquartered in Vancouver, British Columbia, is a clinical-stage biotechnology company focused on the development of targeted immunotherapy for advanced breast cancer.

BriaCell hopes to develop and market the first off-the-shelf personalized immunotherapy for the treatment of advanced breast cancer.

The results of two previous proof-of-concept clinical trials produced encouraging results in patients with advanced breast cancer. Most notably, one patient with breast cancer that had spread to other sites (metastatic cancer) responded to Bria-IMT™ with a substantial tumor shrinkage in multiple sites including the breast, the lung, soft tissues and even the brain. Similar observations have been confirmed more recently in additional patients, and BriaCell is developing BriaDX™ as a way to identify those patients most likely to respond.

BriaCell has recently completed recruitment of a Phase I/II study (NCT03066947) of Bria-IMT™, the Company’s lead product candidate, in advanced breast cancer patients showing an outstanding safety profile and excellent efficacy. BriaCell is currently enrolling advanced breast cancer patients in a combination therapy trial (NCT03328026) of Bria-IMT™ with Keytruda® (Keytruda® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.) or Yervoy® (Yervoy® is a registered trademark of Bristol-Myers Squibb Company). For further information on the Phase IIa clinical trials, please visit trial NCT03066947 and trial NCT03328026.

BriaCell’s pipeline also includes Bria-OTS™, the first off-the-shelf personalized immunotherapy for advanced breast cancer; and, a companion diagnostic product BriaDX™. By using BriaDX™ to identify and treat the patients who would most likely benefit from their immunotherapies, BriaCell expects to personalize the treatment for the patients, and bring hope to thousands of cancer patients who currently have few-to-no treatment options.

Breast Cancer Statistics

The National Cancer Institute estimates that more than 265,000 new cases of female breast cancer will be diagnosed in the U.S. during 2018, and that more than 40,000 women in the U.S. will die from the disease. Approximately 12 percent of women will be diagnosed with breast cancer at some point during their lifetime, based on 2013-2015 data.

Using its novel technology platform and strong R&D capabilities, BriaCell believes it has the opportunity to address this market, as well as have the opportunity to develop immunotherapy candidates for other cancer indications.

The global cancer immunotherapy market is expected to reach nearly USD$203 billion by 2025.

BriaCell Therapeutics Corp. (BCTXF), closed the day's trading session at $0.07, up 1.45%, on 3,460 volume with 2 trades. The average volume for the last 3 months is 16,328 and the stock's 52-week low/high is $0.0495/$0.135.

Recent News

chart

Marijuana Company of America Inc. (MCOA)

The QualityStocks Daily Newsletter would like to spotlight Marijuana Company of America Inc. (MCOA).

Marijuana Company of America Inc. (OTCQB: MCOA) was featured today in a report by CannabisNewsWire. Have you ever wondered which delivery method offers the best results when you are consuming cannabis? A recent study has concluded that “dabbing” is superior to the other common ways of getting cannabis into your bloodstream.

Marijuana Company of America Inc. (OTC: MCOA) (the “Company”) are pioneers in the cannabis industry going back to 2009 when Don Steinberg, MCOA’s CEO, founded the first marijuana company ever to trade on a U.S. stock market, Medical Marijuana Inc. Since then, Don and his partner, Charlie Larsen, have formed Global Hemp Group and Marijuana Company of America. They have experienced the shift of legislation first hand, not only for the legalization of marijuana but also the emerging hemp-based CBD products.

The CBD market is growing exponentially and consequently the founders of MCOA have constructed their business model around the development of industrial hemp-based CBD products. The industrial hemp plant can be used to produce products that are carbon neutral or even carbon negative. It is one of the longest, strongest natural fibers on earth, used as a building material that is free of mold, pesticide-resistant, and fire proof. Hemp has also been described as a “super food,” which provides additional business opportunities. No part of the plant is left unused and the Company’s overall strategy is to take advantage of every profit center from farm to the multiple valuable finished products.

The cannabis and hemp industries are experiencing unprecedented growth that is expected to continue for many years as these industries are now accepted globally and continue to mature and expand. North American consumers spent $6.7 billion on legal cannabis products in 2016, up 34% from 2015’s $5 billion. This trend is widely expected to explode at a 27% compounded annual growth rate to reach $22.6 billion by 2021, according to ArcView Market Research.

The company offers investors the opportunity to be on the forefront of cannabis and hemp innovation through cultivation, processing in the legal cannabis and industrial hemp sectors. The Company’s business model includes producing a diverse portfolio of synergistic business segments that provide value to its shareholders. Its vertically integrated business model and distribution platforms are positioned to capture market share by developing recognizable and valuable brands.

Under the MCOA umbrella, wholly owned subsidiary hempSMART™, Inc. is committed to bringing high quality CBD-based products to the market through its affiliate marketing program. Through hempSMART, MCOA’s strategic approach to the distribution of products is through a networking architecture geared to maintain customer loyalty and capture market share. The patent-pending product “hempSMART Brain,” is designed to revolutionize the safe and effective support of healthy brain function. The brand new product, HempSMART DROPS, is a full-spectrum CBD tincture formulated with hemp and fractionated coconut oils. The hempSMART marketing team has decades of experience, and is well positioned to take the hempSMART brand to a global audience.

Marijuana Company of America Inc. (MCOA), closed the day's trading session at $0.0156, up 2.63%, on 5,593,080 volume with 290 trades. The average volume for the last 3 months is 13,782,778 and the stock's 52-week low/high is $0.0115/$0.0498.

Recent News

chart

Plus Products Inc. (CSE: PLUS) (OTC: PLPRF)

The QualityStocks Daily Newsletter would like to spotlight Plus Products Inc. (CSE: PLUS) (OTC: PLPRF).

Leading California edibles manufacturer Plus Products Inc. (CSE: PLUS) (OTCQB: PLPRF) on February 8, 2019, announced its participation in the newly formed National Cannabis Roundtable (“NCR”), a campaign aimed at reforming federal cannabis laws and advocating for a rational legal framework. To view the full press release, visit: http://nnw.fm/iZlC2.

Plus Products Inc. (CSE: PLUS) (OTC: PLPRF) is a branded cannabis-infused products manufacturer of edibles created to support a healthy and active lifestyle. Headquartered in San Mateo, California, PLUS™ concentrates on producing edibles using extracts to ensure compliant, dosable and delicious products that provide a consistent cannabis experience.

First introduced to the market in 2015 to rave reviews, PLUS™ is now one of the top best-selling edible brands in California. PLUS™ operates through a wholly owned subsidiary, Carberry, and has four cannabis-infused gummy candy SKUs (in addition to limited edition SKUs), that are currently sold in over 200 licensed dispensaries and delivery services. All products under the PLUS™ brand are produced in the company’s 12,000-square-foot food-safe cannabis manufacturing facility in Adelanto, California.

PLUS Products shares are currently listed on the Canadian Securities Exchange. PLUS™ raised CAD$20 million through the offering, for which the lead underwriters were PI Financial and Canaccord Genuity. The company intends to use a portion of the IPO proceeds to fund rapid product capacity expansion, factory automation, working capital and new product development.

Operating in the largest adult-use recreational market in the U.S., PLUS Products holds a temporary manufacturing license in California and was one of the first brands to bring fully compliant products to the legal market. California legalized adult use recreational sales on Jan. 1, 2018, and industry analysts expect edible sales there will continue to amass enviable revenues. According to BDS Analytics, edibles made up 18 percent of marijuana retail sales in February 2018 across licensed retailers in California, with PLUS™ products ranking in the Top 10 of edible brands by retail dollar sales.

During the first half of 2018, PLUS Products generated US$2.45 million in sales, a marked improvement over 2017’s US$1.07 million in sales. The company’s established cannabis products are not only compliant with state laws, they are proving to be extremely popular with consumers. Among the PLUS™ product brands are:

  • Blackberry & Lemon RESTORE, an infusion of carefully dosed cannabis with a 9:1 THC to CBD per gummy.
  • Sour Watermelon UPLIFT, a low-calorie gummy crafted from carefully dosed cannabis with an infusion of 5mg THC per gummy.
  • Pineapple & Coconut CBD RELIEF, a tropical flavor gummy made from pure cannabis-derived CBD that is low-calorie, gluten-free and made with kosher ingredients.
  • Sour Blueberry CREATE, a low-calorie gummy infused with hybrid flower containing 5 mg THC.
  • Limited Edition Rose & Vanilla, available at select locations during Winter 2018, these gummies are crafted with 60 mg THC/30 mg CBD per tin.
  • Limited Edition RAINBOW SORBET gummies was created to celebrate Pride during Spring 2018 with a portion of each purchase donated to The Trevor Project, a confidential suicide hotline for LGBT youth.

“We are extremely proud of the products PLUS has brought to market,” remarked Jake Heimark, CEO and cofounder in a statement. “We’ve quickly grown into one of the leading edible brands in California. With the proceeds of this round, we will continue to further our mission: to make cannabis safe and approachable for all types of consumers.”

The PLUS™ team believes that everyone deserves access to consistent, dosable and delicious cannabis products and strives to make that happen. Producing the best infused products at scale requires thoughtful collaboration among experts in many fields. At PLUS™, our team is comprised of Chefs, Chemists, Food Manufacturing Experts, Engineers, Machinists, Visionaries, Creatives, Strategists and others.

Plus Products Inc. (PLPRF), closed the day's trading session at $5.51, off by 4.13%, on 160,271 volume with 550 trades. The average volume for the last 3 months is 141,689 and the stock's 52-week low/high is $2.81/$6.01.

Recent News

chart

Green Growth Brands Inc. (CSE: GGB) (OTCQB: GGBXF)

The QualityStocks Daily Newsletter would like to spotlight Green Growth Brands Inc. (OTCQB: GGBXF).

Green Growth Brands Inc. (CSE: GGB) (OTCQB: GGBXF) ("GGB" or "the Company") today announced that it has entered into an agreement through which the Company will gain access to 108 prime shop locations in U.S. malls owned and operated by the Simon Property Group, Inc. (NYSE: SPG) ("Simon").  Pursuant to the arrangement, GGB will further expand its chain of CBD-infused personal care product shops under the Seventh Sense Botanical Therapy ("Seventh Sense") brand and other GGB brands. The Seventh Sense brand offers high quality CBD-infused products at affordable prices.

Green Growth Brands Inc. (CSE: GGB) (OTCQB: GGBXF) is a lifestyle-oriented cannabis and cannabidiol (“CBD”) consumer products company with a portfolio of lifestyle brands customized to connect specific, like-minded customers. Each Green Growth Brand provides the best quality products within a retail experience that appeals to users in an environment that is emotionally branded and easy to navigate.

In the next five years, the cannabis industry will generate more than $28 billion of new revenue from an estimated 14 million new customers, according to Ackrell Capital’s 2018 Cannabis Investment Report. Meanwhile, Hemp Business Journal projects that the CBD market will increase 8x to $3 billion by 2021, up from $200 million in 2017. Green Growth Brand intends to dominate in these markets with a lineup up products grown, manufactured and presented with the highest quality standards in mind.

Products under the Green Growth Brand umbrella include:

  • CAMP: A kiosk-type store where consumers can experience beautifully crafted lifestyle products that enhance one’s journey to self-discovery.
  • Seventh Sense: A CBD-infused body care collection crafted from the finest botanicals and fragrances on earth. Created to maximize the properties and aromatics of each ingredient, Seventh Sense natural products are CBD-infused botanical therapy.
  • Meri+Jayne: Fiercely authentic and wholly unapologetic, Meri+Jayne is a youthful, full-on celebration of what makes each person unique. Expect the unexpected when it comes to this mix of amazing products.
  • Green Lily: A place for women to explore a new world of wellness. With advice on every product, from efficacy to usage, Green Lily guides guests through beautiful new ways to experience cannabis and CBD.
  • The +Source: Located in Las Vegas and Henderson, Nevada, The+Source dispensaries operated by Green Growth Brands serve both medical patients and retail customers. Green Growth Brands also operates a grow and production facility in Post, Nevada, and recently entered into definitive agreements to acquire a Pahrump, Nevada, cultivation facility.
  • XanthicBiopharms is the owner of valuable intellectual property that turns THC(Tetrahydrocannabinol) and CBD into a water-soluble substance. As a result of combining Green Growth Brands and Xanthic, this technology is being used to create incredible new products.

Business Strategy

Green Growth Brands has identified numeroushitches in the current cannabis retail space. The company intends to counter these challenges and provide a customer experience ripe with a friendly staff, in-stock assortments, efficient operations and more. The company’s retail partners provide distribution opportunities within 4,000 stores, as well as robust and established digital platforms to best reach the modern consumer.

Management

Green Growth Brands brings together a collection of expert retailers, scientists, botanists, developers, artists and business leaders for the benefit of building community. Led by an executive management team steeped in decades of experience with several of America’s most successful brands, including Victoria’s Secret, American Eagle Outfitters, Bath & Body Works, Limited Brands and Designer Shoe Warehouse, Green Growth Brands is uniquely positioned to create memorable brands, retail experiences, and quality products for the emerging cannabis industry.

Chief Executive Officer Peter Horvath heads strategy and execution across all company channels, and previously took shoe retailer DSW public on the NYSE at $1.5 billion. As a dynamic, creative brand leader, team builder, and specialty retail veteran with deep roots in finance, Horvath’s unique ability to understand the big picture while never missing the subtle details is a critical factor in Green Growth Brands’ success and brand popularity among customers.

Chief Marketing Officer Scott Razek is a brand strategist, storyteller and strategic marketer. Razek‘s 25 years of experience in brand building, product development and customer experience focus are a key differentiator for the Green Growth Brands portfolio.

CAO Ed Kistner brings 33 years of multifaceted experience at leading retail businesses, notably in finance, merchandise planning, operations and stores. His well-rounded experiences in fast-changing environments position Kistner to be the architect of the operational execution at Green Growth Brands.

CSO Kellie Wurtzman brings significant retail leadership to Green Growth Brands with a proven track record of leading high-performance stores and teams across multiple retail sectors. Her unmatched experience in identifying and supporting developing business opportunities is ideal for evolving the cannabis industry and will be instrumental in expanding operations at Green Growth Brands.

Headquartered in Columbus, Ohio, Green Growth Brands is traded on the Canadian Securities Exchange and on the OTCQB, providing investors with increased access to data, transparency and liquidity.

Green Growth Brands Inc. (OTCQB: GGBXF), closed the day's trading session at $4.2955, off by 0.98%, on 272,926 volume with 824 trades. The average volume for the last 3 months is 186,718 and the stock's 52-week low/high is $1.8068/$5.205.

Recent News

chart

The Green Organic Dutchman (TSX: TGOD) (OTC: TGODF)

The QualityStocks Daily Newsletter would like to spotlight The Green Organic Dutchman (OTC: TGODF).

Established in 2012, The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (OTCQX: TGODF) focuses on the production of premium certified organic cannabis. The company’s organic process includes living soil, sustainable energy and laboratory certification and testing. Also today, the company was highlighted in an article looking at companies in the cannabis space worth further investigation. January’s bull run for the cannabis industry led to a natural correction, it looks like the sector is gaining support for its next push, there are several opportunities in the cannabis space you should begin researching.

The Green Organic Dutchman (TSX: TGOD) (OTC: TGODF), whose principal location is in Hamilton, Ontario, produces farm grown, organic, pesticide-free medical cannabis in small batches using all natural, organic craft growing principles. TGOD is licensed under the Access to Cannabis for Medical Purposes Regulations (ACMPR) to cultivate medical cannabis. The company carries out its principal activities producing cannabis pursuant to the provisions of the ACMPR and the Controlled Drugs and Substances Act (Canada).

Committed to becoming the global leader in delivering organic cannabis solutions that enhance people’s lives, TGOD consistently adheres to the highest levels of excellence. Its world-class management team includes a proven group of leaders with outstanding executive and operational experience specific to consumer packaged goods, consumer products, cannabis and finance industries.

TGOD is positioned as one of the highest quality and most cost efficient cannabis producers in Canada by leveraging innovative technology and low-cost power solutions. It holds one of the largest land packages under a single ACMPR license in Canada, providing future cannabis Agri-park style development and opportunities for joint ventures, licensing and distribution partners. Its industry leading alliance partners include Eaton, Ledcor Group and Hamilton Utilities Corp.

Eaton is the second largest power management company in the world and promises to supply innovative and cost effective power solutions to meet TGOD’s growing demands. Construction management is supplied by Ledcor, Canada’s second largest multidisciplinary construction company and a pioneer in the Green Building Industry. An alliance with Hamilton Utilities Corp allows TGOD to reduce its power costs from $0.13 per kWh to less than $0.05 per kWh. Greenhouse design is provided by Larssen Greenhouse, whose 25-plus years of experience in building some of the most modern and sophisticated greenhouses in the industry will provide TGOD with state of the art, climate-controlled hybrid greenhouse solutions.

Canada is quickly becoming a hub for cannabis investors with over $1.3 billion raised by Canadian companies to date. There are 58 licensed producers to service a population of 36 million and only two organic producers. TGOD, which holds licenses in Ontario and Quebec, is strategically located in both provinces that together claim 22 million Canadians as residents. Another estimated 57 million people live next door in six U.S. bordering states.

The Canadian cannabis market currently has a massive supply demand gap, which makes TGOD’s expansion plans even more important to investors. These plans include a combined build-out capacity of 970,000 square feet, allowing TGOD to produce 116,000 kg annually of organic cannabis. Upon completion, Phase One in Hamilton, Ontario, which is fully funded, will provide 150,000 square feet of growing capacity capable of producing up to 14,000 kg of cannabis or $112 million in revenue at $8 a gram.

The company’s Quebec expansion will be constructed on a recently secured 75-acre property near Montreal. This new property has a planned expansion of 820,000 square feet capable of producing 102,000 kg of organic cannabis. The first phase of this expansion is underway and construction is expected to be completed by the end of 2018. Quebec’s first phase will consist of 220,000 square feet capable of producing 22,000 kg of cannabis. Two additional expansion phases will add 250,000 square feet (26,000 kg of cannabis) and 350,000 square feet (54,000 kg of cannabis). Power costs remain exceptionally low for both facilities with access to all other needed utilities available and close by.

TGOD also plans to gain a share of the burgeoning cannabis oils market which by Q1 2017 accounted for 49 percent of all cannabis sold in Canada under the ACMPR, up from only 27% in Q2 2016. TGOD has ordered a purpose-built extraction laboratory with an estimated commission in Q4 of 2017. This is a commercial-scale CO2 extraction unit capable of processing up to 12,000 kg of raw material per year and producing approximately $170 million worth of organic cannabis oils. Raw cannabis oil provides a significant downstream manufacturing opportunity into several potential recreational market verticals including edibles, beverages, topicals and concentrates.

Data from the Canadian ACMPR Market Trends report indicates a rising number of consumers will continue to seek out healthier, less conspicuous ways to consume cannabis, ensuring sales of organic cannabis oil products remain brisk. Organic cannabis products demand a significant premium compared to non-organic products and the demand keeps growing.

Plans to take the company public are underway with an initial public offering (IPO) slated for January 2018. In November, the company raised $13 million in equity financing and in March closed a $27 million non-brokered private placement. Another $20 million is currently being raised before the IPO in January, which will be utilized for expansion plans.

TGOD is uniquely positioned between the medical and recreational cannabis industry since Canada is scheduled to legalize cannabis for all adults in mid-2018. As of August 2017, TGOD has 2,400 shareholders. Established in 2012, TGOD’s motto, “Making Life Better,” can be seen in its strategic partnerships, top quality management team, and dedication to organic farming and principles.

To learn more about the company and how to invest, contact TGOD directly at financing@tgod.ca

The Green Organic Dutchman (OTC: TGODF), closed the day's trading session at $2.40, off by 5.88%, on 986,469 volume with 1,365 trades. The average volume for the last 3 months is 912,450 and the stock's 52-week low/high is $1.607/$7.894.

Recent News

chart

TransCanna Holdings Inc. (CSE: TCAN)

The QualityStocks Daily Newsletter would like to spotlight TransCanna Holdings Inc. (CSE: TCAN).

TransCanna Holdings (CSE: TCAN) (FSE: TH8), through its affiliate TCM Distribution Inc. (“TCMD”), has secured local licenses in Adelanto, California, and recently secured a California temporary distribution license. In addition, TransCanna also completed its initial public offering (“IPO”) for total gross proceeds of C$2.2 million, which will be used to fund its general working capital for the next 12 months including its entry into California’s cannabis transportation and branding market, per a prospectus filed on SEDAR in December (http://nnw.fm/lMN9w). To view the full article, visit: http://nnw.fm/ZLu9H.

TransCanna Holdings Inc. (CSE: TCAN) through its subsidiaries specializes in assisting clients who are cannabis farmers and manufacturers get recognized by end consumers who in turn purchase their products. TransCanna offers or will be offering services to support almost every aspect of the cannabis-related eco-system; from branding and design, to transportation and distribution, to marketing and sales.

California’s legalized adult-use recreational marijuana market opened for business January 1, 2018. The state’s Bureau of Cannabis Control is responsible for regulating all commercial activities in the state including cultivation, distribution and transportation. Moving cannabis products in the California marketplace is extremely challenging due to municipal and state laws and regulations, which can differ among cities and counties. Since cannabis remains illegal under federal law, Department of Transportation regulated companies are barred from participating in the market, which means companies looking to excel in the sector must hold a state-issued distributor license from the Bureau of Cannabis Control.

TransCanna has already entered into an Intellectual Property Rights and Royalty Agreement for the Track & Trace software platform required by the state of California. TCM Distribution, the operating company managed by TransCanna, has received a transportation and distribution permit from the city of Adelanto and a temporary transportation and distribution permit from the state of California. TransCanna has also executed a land lease to build a 10,000-square-foot transportation and distribution facility in Adelanto.

TransCanna is strategically creating a distribution network throughout California that places its facilities no further than a three-hour drive from most any client. The company is in the process of leasing or purchasing properly licensed and permitted warehouses strategically located throughout California along with new secure trucks, sprinter vans and/or armored vehicles.

TransCanna plans to create its own portfolio of branded products for the cannabis and hemp sectors. The company’s management team intends to translate the skills, knowledge and experience gained from a combined 60 years of branding and marketing experience in the music, professional sports and alcohol industries into TransCanna and the cannabis industry.

As part of the “TransCanna Way,” the company intends to manage most aspects of the supply chain from upper end procurement, branding, transportation and distribution, to marketing and sales.

Leading TransCanna as its CEO and chairman is James Pakulis, who has three decades of experience working with public and private entrepreneurial companies in a variety of emerging and high-growth sectors. He is formerly the president and a director of Lifestyle Delivery Systems Inc. (CSE: LDS) (OTCQB: LDSYF), a vertically integrated cannabis-related entity operating in California. Pakulis was chairman and CEO of General Cannabis Inc. which from 2010 to 2012 owned WeedMaps. Pakulis oversaw the company’s growth from zero to over $16 million in annual revenue in less than 24 months.

The company’s strategic advisors include individuals with extensive experience in branding, marketing, sales, distribution, production and supply chain management.

For additional information, call: (604) 609-6199

TransCanna Holdings Inc. (CSE: TCAN), closed the day's trading session at $2.07, off by 2.36%, on 64,327 volume with 67 trades. The stock's 52-week low/high is $0.769/$2.59.

Recent News

chart

Supreme Cannabis Company Inc. (TSX.V: FIRE) (OTC: SPRWF)

The QualityStocks Daily Newsletter would like to spotlight Supreme Cannabis Company Inc. (OTC: SPRWF).

Supreme Cannabis Company Inc. (TSX.V: FIRE) (OTC: SPRWF) was highlighted today in a report published by StockPrice.com. The marijuana stock market has occupied media headlines over the course of the past couple of years, during the course of which top players in the industry saw huge boosts in investor interest. With the increase of capital and new business entering the market, the cannabis sector has shown serious promise in terms of generating potential opportunities.

Supreme Cannabis Company Inc. (TSX.V: FIRE) (OTC: SPRWF), is committed to providing premium brands and products that reflect the company’s knowledgeable customers, passionate employees, and culture of innovation. Supreme Cannabis’ mission is to grow the world’s best cannabis and become a leader in the global industry. The company calls its Toronto Venture Exchange stock symbol FIRE “a testament to our passion for cannabis and our obsession with quality.”

Supreme Cannabis believes the world is ready to follow Canada’s lead by ending the 100-year cannabis prohibition and, as Canada’s only coast-to-coast premium cannabis producer, the company sees itself at the center of this global shift.

In August 2018, Supreme Cannabis uplisted its shares to the to OTCQX market in the U.S., where the company trades under the ticker symbol SPRWF. The following month Supreme reported record Q4 revenues of CAD$3.55 million, a 71-percent increase over the previous quarter. Supreme Cannabis also recorded revenue of CAD$8.85 million for its fiscal year ended June 30, 2018, placing it among publicly traded Canadian cannabis companies with the highest reported revenue in their first four quarters of sales.

“As a result of the successful execution of our strategy, we have generated significant revenue growth both for the quarter and the year-end period,” Supreme Cannabis CEO Navdeep Dhaliwal stated in a news release. “We look forward to building on this growth as we expand domestically and internationally.”

The company’s growth strategy includes key industry agreements, such as its CAD$12 million supply agreement with Tilray Inc. (OTC: TLRY), a global leader in cannabis research, cultivation, processing and distribution. The agreement calls for Supreme to supply Tilray with dried cannabis for support of medical cannabis patients in Canada for the period of one year.

Another key component is the company’s wholly owned 7ACRES subsidiary. The 7ACRES cultivation facility, one of the first 40 federally licensed cannabis producers in Canada, is focused on building a core competency in scaled cannabis production, which will give 7ACRES the needed flexibility to maintain leadership in the industry as the Canadian market grows and matures. Though 7ACRES is Supreme Cannabis’ flagship brand and only currently operating business unit, the company will continue to identify new opportunities to grow its portfolio of companies and build innovative cannabis businesses throughout the world.

7ACRES operates from a 342,000-square-foot cultivation facility in Kincardine, Ontario, and has been federally licensed since 2016. Current capacity is 13,333 kilograms dried cannabis annually, with plans to ramp up production by mid-2019 to a rate of 50,000 kilograms per year.

Supreme Cannabis seeks to differentiate 7ACRES from other licensed cannabis producers by producing premium quality product sustainably at scale. “Craft quality, commercial scale” is a slogan the company uses, and the Kincardine greenhouse employs state-of-the-art technology and cultivation best practices to strive toward that goal. Supreme identifies the quality of the 7ACRES product as the company’s primary strength and says a shared “passion for the plant” is the driver of company culture. Six Canadian provinces have signed supply agreements with Supreme, a fact the company credits to the high quality of 7ACRES cannabis.

Its customers, Supreme Cannabis management says, are informed and discerning regarding cannabis, and they value a premium brand that respects their product knowledge. The company believes its high regard for customers, premium product quality, and mass cultivation capability has allowed Supreme Cannabis to emerge as Canada’s preeminent premium cannabis producer. In the Canadian cannabis market, the company has established 7ACRES as a premium brand that’s distributed coast-to-coast and commands premium pricing. The 7ACRES brand is already listed as premium cannabis product in all provinces that disclose their cannabis listing categories, and 7ACRES on average wholesales for up to one-third higher in price than other brands in the Canadian cannabis market.

To further its distribution, in the medical cannabis market Supreme Cannabis has partnered with several Canadian cannabis retailers including Aurora Cannabis, Emerald Health Botanicals, Namaste, Zenabis, and others. The company’s investment portfolio also includes an equity position and long-term global distribution partnership with Medigrow, based in Lesotho, targeting the export of medical cannabis oil for the international market.

Supreme Cannabis seeks to make the company an innovator in the cannabis sector regarding design of cultivation facilities and development of operation excellence metrics. The management team is confident that the 7ACRES flagship brand, the company’s proprietary technology and products, and the company’s culture of passion for cannabis will deliver consistent long-term shareholder value.

Supreme Cannabis Company Inc. (OTC: SPRWF), closed the day's trading session at $1.45, off by 0.68%, on 706,891 volume with 753 trades. The average volume for the last 3 months is 416,740 and the stock's 52-week low/high is $0.85/$2.04.

Recent News

chart

Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (LXRP).

The cannabis industry is experiencing impressive growth thanks to both legal and social changes worldwide, and big corporations are stepping up to invest. In a new Audio Press Release (“APR”), CannabisNewsAudio praised Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) (http://nnw.fm/iY84s) for building a large funding deal on its own terms.

Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP) has developed and out-licenses its proprietary technology for improved taste, rapidity, and delivery of bioactive compounds, including nicotine and cannabinoids. To achieve higher absorption rates and fast onset, consumers traditionally defaulted to smoking. Lexaria provides a superior administration method by delivering these substances through a patented process within edible food products, thus eliminating all the harmful health consequences of smoking.

Lexaria’s technology is unique in that it takes advantage of GRAS (Generally Recognized As Safe) food ingredients processed with its patented DehydraTECHTM technology to improve taste, remove odor, and decrease the time to onset of bitter-tasting drugs. Lexaria is primarily a B2B enterprise and has existing cannabinoid licensing agreements with companies in Canada, the largest-market states in the United States, and internationally. Lexaria has entered into a R&D partnership with one of the largest cigarette companies in the world for oral forms of nicotine delivery. Lexaria has also developed its own brands partly for demonstration purposes, utilizing its patented technology to infuse hemp oil ingredients within popular foods such as coffee, tea, and supplements. These brands include ViPova™ and TurboCBD™.

In 2015, Lexaria commissioned an independent third-party lab to test its technology under carefully monitored in vitro conditions. Results showed that the company’s technological process and lipid formulation improve intestinal absorption as much as 500%. Lexaria has conducted multiple rounds of studies including in vivo and human clinical. In absorption studies conducted on rats, for example, Lexaria detected nicotine in the animal’s bloodstream just two minutes after it entered the stomach. In a randomized, double blinded human clinical study, cannabidiol (CBD) was measure in the human bloodstream at a 317% higher rate 30 minutes after swallowing a capsule processed with DehydraTECH than a non-enhanced capsule of equal strength.

Lexaria also has an R&D partnership with the Canadian government’s National Research Council. That R&D is expected to characterize molecular bond formation theorized to occur with Lexaria’s unique technology between the lipid delivery agents and the bioactive substances it processes and combines. Results from this R&D have helped support B2B relationships with Fortune 500 companies. Lexaria has four distinct subsidiaries that focus on different market sectors: Hemp/CBD; Pharmaceutical; Cannabis; and Nicotine.

Aside from testing, a critical component of Lexaria Bioscience’s business model is a strong and growing intellectual property portfolio. As of the end of 2018, the company’s patent portfolio includes 53 patent applications filed and pending in more than 40 countries around the world; and 10 patents granted to date. Lexaria is expecting additional new patent awards both in the U.S. and internationally in 2019 and beyond. Some of its more recent areas of investigation have included human hormones and erectile dysfunction substances, among others.

Royalties play a vital role in Lexaria’s revenue-generating business model. The company out-licenses its technology (royalty) to third-partners and has signed royalty deals with start-up companies as well as with a Fortune 100. The company’s growth initiatives are guided by a management team headed by CEO Chris Bunka, a serial entrepreneur who has contributed to several multi-hundred million-dollar valuations over the course of his career. He is supported by a growing team of professionals with extensive experience in pharmaceutical and bioscience sectors, invention, toxicology, consumer goods, and other relevant skillsets.

Lexaria Bioscience Corp. (LXRP), closed the day's trading session at $1.30, off by 2.99%, on 67,565 volume with 110 trades. The average volume for the last 3 months is 183,875 and the stock's 52-week low/high is $0.75/$2.43.

Recent News

chart

Cannabis Strategic Ventures, Inc. (NUGS)

The QualityStocks Daily Newsletter would like to spotlight Cannabis Strategic Ventures, Inc. (NUGS).

Cannabis Strategic Ventures (OTC: NUGS), a Los Angeles-based cannabis industry incubator, recently announced its plan to uplist to the OTCQB Venture Market, a milestone that falls in line with the company’s acquisition-based growth strategy. To view the full article, visit: http://nnw.fm/6xPMR.

Cannabis Strategic Ventures, Inc. (NUGS), headquartered in Los Angeles, California, is focused on supporting entrepreneurial growth within the fast-growing legal cannabis sector. Through a selective portfolio of subsidiaries, Cannabis Strategic Ventures offers outsourced personnel solutions tailor-made to match the growth dynamics of cannabis cultivators, manufacturers, dispensaries and other cannabis marketplace participants. The company also pursues investment opportunities in the areas of real estate, cultivation, extraction, distribution, packaging, dispensary operations, and branded products within the cannabis space.

The legalization of adult-use sales in California is expected to create nearly 99,000 cannabis industry jobs in the state by 2021, representing about a third of all cannabis jobs nationwide, and 146,000 jobs overall when indirect and induced efforts are considered, according to Arcview Market Research. By 2021, direct cannabis industry employment will top 291,500 FTE jobs, with a total employment effect of nearly 414,000 FTEs across all legal cannabis states, according to the report.

Cannabis Strategic Ventures believes its staffing capabilities will be in a similar state of demand. The company in April 2018 completed a definitive agreement to acquire Worldwide Staffing Group, Inc., which booked approximately $1.5 million in revenues in 2017.

Worldwide will operate within Cannabis Strategic Ventures as an independent and separate wholly owned subsidiary providing strictly non-cannabis related employment and staffing services. As Worldwide continues to expand its operations in general clerical and administrative, marketing, accounting, and other verticals, Cannabis Strategic Ventures will leverage the subsidiary’s expertise to expand its business operations further into the cannabis staffing arena, with an emphasis on the California markets.

Cannabis Strategic Ventures’ BudHire™ subsidiary is an outsourced employment service specifically designed to meet the needs of growing cannabis-related business operations, utilizes a proven recruiting formula to match the most qualified candidates to a broad spectrum of cannabis-related jobs. Under the BudHire™ brand, Cannabis Strategic Ventures offers temporary, seasonal, permanent staffing solutions, as well as professional employment organization services and human resources consulting to the cannabis industry.

Cannabis Strategic Ventures portfolio also includes Pure Applied Sciences Inc. and its brand “PureOrganix™,” a line of high quality concentrate, organic and pure cannabis oils that conform with Current Good Manufacturing Practices (cGMP) and meet FDA guidelines for Active Pharmaceuticals Products (API). The acquisition includes all intellectual properties, including formulations and technologies, and related accessories of Pure Applied Sciences.

Cannabis Strategic Ventures Pure Applied Sciences subsidiary, has a cannabis concentrate extraction services agreement with CP Logistics LLC (“CPL”), a wholly owned U.S. subsidiary of Sunniva Inc. (CSE:SNN) (OTCQX:SNNVF). Under this agreement, CPL will perform white label services producing high quality, ultra-purified cannabis extracts out of its Sun-Oil Facility in Cathedral City, California, for Pure Applied Sciences under the Pure Organix brand name.

The management team at Cannabis Strategic Ventures believes there is incredible opportunity to carve-out and control specific industry niches, to create unique cannabis consumer branded products, and to expand into other sub-sectors of the cannabis marketplace.

Cannabis Strategic Ventures, Inc. (NUGS), closed the day's trading session at $1.25, off by 8.09%, on 400,579 volume with 218 trades. The average volume for the last 3 months is 108,648 and the stock's 52-week low/high is $1.02/$5.94.

Recent News

chart

FinCanna Capital Corp. (CSE: CALI) (OTCQB: FNNZF)

The QualityStocks Daily Newsletter would like to spotlight FinCanna Capital Corp. (FNNZF).

FinCanna Capital Corp. (CSE: CALI) a royalty company for the U.S. licensed medical cannabis industry is pleased to announce that further to its news release of January 11, 2019 wherein it announced the closing of the first tranche of its oversubscribed Secured Convertible Debentures (“Debentures”) financing of $2.4 million, FinCanna has upsized and closed the second and final tranche of the financing for an additional $2.4 million.  The aggregate proceeds of this financing total $4.8 million.

FinCanna Capital Corp. (CSE: CALI) (OTCQB: FNNZF) is a royalty company aiming to be the capital partner of choice for high-growth, best-in-class businesses operating in the licensed U.S. medical cannabis industry. Primarily focused on the burgeoning California cannabis market, FinCanna leverages extensive investment expertise and industry experience to benefit its shareholders and portfolio companies.

Medical Cannabis Market

According to Ameri Research, the global market for licensed medical cannabis is growing at a compound annual growth rate (CAGR) of more than 21%, on track to exceed $63.5 billion by 2024. Within this market, FinCanna has identified considerable opportunity in California, the fifth largest economy in the world and the largest medical cannabis market in North America. Arcview Group forecasts California’s legal cannabis industry will grow at 21.1% CAGR to $6.5 billion in 2020, generating more than $1 billion in tax revenue.

Royalty Model & Portfolio

FinCanna’s “whole capital” solution for businesses in the licensed medical cannabis sector includes the provision of capital investment for a percentage of their future revenues. The FinCanna Capital Solution utilizes a royalty arrangement to deliver capital, in order to facilitate the growth or other specific objectives of its investees, and ensure the business opportunity is optimized. This model provides an alternative or complement to debt and equity financing, allowing investees to maintain financial flexibility and control of their business rather than entering into arrangements that may include restrictive debt structures or giving up an ownership stake.

FinCanna’s portfolio includes Cultivation Technologies, Inc. (“CTI”), a team of experts from Fortune 150 agriculture, medical cannabis, law, engineering and technology companies. FinCanna is providing funding to CTI for its planned, fully entitled, large-scale indoor medical cannabis facility to be developed in Coachella, California.

CTI has established an interim medical cannabis extraction facility (the “Interim Facility”) that will produce licensed medical cannabis products until the Coachella Project is complete. CTI is currently expanding its product line, Coachella Premium, to include vaporizer cartridges. Initial market feedback gathered during the product development phase indicates that Coachella Premium’s vaporizer cartridges offer a unique proposition within the vaporizer market, one of the fastest growing verticals in the cannabis market.

The Interim Facility can process up to 6,000 pounds of biomass per month, the equivalent of approximately 3.7 million grams of raw oil per year, with room for expansion. It is expected that the completed Coachella Project will be able to process 30,000 to 50,000 pounds of biomass per month, or the equivalent of 18 million grams to 30 million grams of raw oil per year.

Additionally FinCanna has entered into a royalty agreement with Green Compliance, a provider of point-of-sale software solution (“ezGreen”) for licensed medical cannabis dispensaries and cultivators. Green Compliance helps its customers comply with both the Health Insurance Portability and Accountability Act (“HIPAA”) and State Laws by ensuring patients’ confidential data is being handled properly, helping to protect from possible security breaches and financial and criminal liability resulting from potential violations.

FinCanna has also signed binding term sheet with Oakland, California-based Gram Co Holdings, subject to due diligence by FinCanna. Gram Co is a cannabinoid research and refinement facility focused providing B2B and B2C products and services to licensed medical dispensaries, infused product manufacturers, and numerous others in the cannabis supply chain. The company is also retrofitting a large, state-of-the-art medical cannabis extraction laboratory, which is expected to be operating in 2018.

The foregoing contains forward-looking statements regarding Cultivation Technologies Inc. (“CTI”) which are subject to risks, uncertainties and contingencies which include, but are not limited to the statements relating the future construction and completion of the CTI medical cannabis facility in Coachella, California, and the projected biomass processing and raw oil production at the facility. Such forward looking statements are based on assumptions regarding the construction, completion and operations of CTI’s proposed facility, including that CTI will obtain the financing required to build and equip its proposed facility, that CTI will obtain the additional financing required operate the facility, that construction facility is completed on time and budget, that CTI obtains state licenses to operate on a permanent basis, and that the equipment used in the cultivation of medical cannabis performs at scale in a similar way it performs at CTI’s pilot tests.

FinCanna Capital Corp. (FNNZF), closed the day's trading session at $0.1184, off by 6.77%, on 12,815 volume with 6 trades. The average volume for the last 3 months is 42,398 and the stock's 52-week low/high is $0.0577/$0.68.

Recent News

chart

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

ActionStockPicksAgressive StocksBetting On Wall StreetCannabisNewsWireGot Stocks?Got Stock Tips?Green Car StocksGreen Energy StocksGreen On The StreetHomeRunStocksMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireQualityStocks MediaQStocksQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsStock BeatsStocks To Buy NowTerrificStocksTiny GemsTip.usTouchdownStocksDaily ToutTraderPower

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.